IBA to Install Four-Room Proton Therapy Solution at Beijing Proton Medical Center
Louvain-la-Neuve, Belgium, 25 th September 2016 - IBA ( Ion Beam Applications S.A. ), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a contract with Medstar (Shanghai) Leasing Co., Ltd, a subsidiary of Concord Medical Services Holdings Limited ("Concord Medical"), for the purchase, installation and maintenance of a proton therapy system. The system will be installed at Beijing Proton Medical Center and be operated by Beijing Proton Medical Center Limited.
IBA will equip the hospital with its Proteus ® PLUS* four-room configuration, including three gantry-rooms and one fixed-beam room. All rooms will be equipped with IBA's last generation Pencil Beam Scanning capability. The contract, including a multi-year comprehensive maintenance contract, is worth more than 70 million EUR and is subjected to financing. IBA expects to book the order in Q4 2016.
Olivier Legrain, Chief Executive Officer of IBA commented, "We are delighted to be enhancing our presence in China, another important indication of the appeal of our offering in the region. We are also pleased to be supporting Beijing Proton Medical Center to advance its vision of bringing proton therapy to more patients in China. IBA's proton therapy technology has been used to treat more cancer patients than any other company in the world. This extensive experience and knowledge of proton therapy technology has allowed IBA to ensure that more patients are able to access this highly accurate form of cancer treatment."
Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented: "We are delighted to see Beijing Proton Medical Center has made a significant breakthrough after so much efforts had been made in these years. It is Concord Medical's first proton therapy center in China and we are glad to have IBA as our equipment vendor. Our partner, China-Japan Friendship Hospital, is a well-known general hospital in Beijing, with outstanding scientific research ability and nationwide brand awareness. Going forward, we will learn from the experience and technology from other advanced proton centers in the world and are committed to providing the best treatment for the cancer patients in China. By carrying out joint clinical research projects with international peers, we hope to achieve more academic breakthrough in proton cancer therapy research. "
- END -
Notes to Editors
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
* Proteus ® PLUS is the brand name of a Proteus ® 235 configuration
About Beijing Proton Medical Center
The Beijing Proton Medical Center is jointly-developed by Concord Medical Services and China-Japan Friendship Hospital. The 5,000 square meter, international-standards medical facility will be equipped with radiotherapy and diagnostic equipment including proton therapy system, linear accelerator, and PET-CT. It will also provide inpatient services to meet patients' specific needs. Concord Medical is committed to providing patients with the most reliable and comprehensive cancer radiotherapy in China
About Concord Medical
Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China. As of June 30, 2016, the Company operated a network of 123 centers with 73 hospital partners that spanned 52 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Concord Cancer Hospital, a private hospital in Singapore in April, 2015.
For further information please contact:
Chief Strategy Officer
+32 10 475 890
Vice-President Corporate Communication
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Jonathan Birt, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
Rx Communications Group (US)
+1 917 322 2571
Last updated on: 26/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.